Dopamine receptor D3, Dopamine receptor D4, and Dopamine receptor D5 (DRD3/DRD4/DRD5)

The D3, D4, and D5 dopamine receptors are distinct subtypes of G protein-coupled receptors (GPCRs) that mediate the diverse physiological effects of dopamine in the central nervous system and peripheral tissues [1.1.2, 1.3.1]. These receptors are categorized into two functional families: the D2-like family (D3 and D4), which inhibits adenylyl cyclase activity via Gi/Go proteins, and the D1-like family (D5), which stimulates adenylyl cyclase via Gs proteins [1.2.1, 1.3.3]. D3 receptors are predominantly localized in the limbic system and are involved in reward processing and emotional regulation, making them key targets for treating addiction and schizophrenia [1.2.2, 1.3.5]. D4 receptors are primarily expressed in the prefrontal cortex and are linked to attention and executive function, with specific genetic variants associated with ADHD [1.1.3, 1.3.2]. D5 receptors, although less abundant than other subtypes, play significant roles in memory, cognition, and the regulation of renal function [1.3.3, 1.4.4]. Pharmacological agents targeting these receptors include atypical antipsychotics like clozapine, which has high D4 affinity, and D3-preferring agonists like pramipexole used in Parkinson's disease [1.1.5, 1.4.2]. A major therapeutic challenge is achieving high subtype selectivity to minimize off-target effects, such as impulse control disorders or metabolic side effects [1.3.5, 1.4.1].

Other names

D3 receptorD4 receptorD5 receptorDRD3DRD4DRD5D3 dopamine receptorD4 dopamine receptorD5 dopamine receptor

Agonism, Antagonism, Partial agonism